导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.36% | 1894/4773 |
| 近一周 | -2.62% | 2703/5462 |
| 近一月 | -5.02% | 2985/5421 |
| 近一季 | -7.01% | 2265/5209 |
| 近半年 | -0.57% | 1339/4920 |
| 近一年 | 5.41% | 1606/4366 |
| 近两年 | 52.71% | 1402/2954 |
| 近三年 | 35.00% | 865/2253 |
| 成立以来 | 60.21% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.87% 2938/4961 |
15.48% 1667/5312 |
- - |
- - |
| 2025 | 23.72% 1850/4813 |
1.02% 1718/3635 |
1.31% 2383/4076 |
19.94% 2069/4524 |
0.78% 1767/4813 |
| 2024 | 15.83% 878/3463 |
2.93% 662/2808 |
-0.81% 845/3014 |
16.87% 1324/3129 |
-2.92% 2209/3463 |
| 2023 | -8.84% 1066/2656 |
4.39% 965/2280 |
-4.20% 1090/2385 |
-2.54% 692/2515 |
-6.46% 1783/2655 |
| 2022 | -18.91% 775/2207 |
-13.05% 691/1919 |
7.18% 516/2016 |
-14.27% 1058/2113 |
1.49% 1248/2208 |
| 2021 | -2.26% 842/1822 |
-1.88% 551/1255 |
3.11% 981/1330 |
-5.04% 768/1466 |
1.74% 815/1822 |
| 2020 | 38.59% 352/1250 |
-8.52% 618/1028 |
13.17% 643/1067 |
15.33% 221/1164 |
16.06% 185/1184 |
| 2019 | - - |
- - |
- - |
- - |
7.27% 459/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 宝盈中证A100指数增强C VS. 长安沪深300非周期A(740101) |